Composition for preventing and/or treating osteoporosis

A technology for osteoporosis and composition, which is applied in the fields of health care products or food and medicine to achieve the effect of preventing various diseases and improving the nutritional level of the human body

Active Publication Date: 2022-03-25
中山莱博瑞辰生物医药有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the loss of trabecular bone mass and structure, as well as BMD, did not explain the increased fracture risk,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing and/or treating osteoporosis
  • Composition for preventing and/or treating osteoporosis
  • Composition for preventing and/or treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Ecdysterone Composition (βEcd-combo) Increases Osteogenesis Test

[0036] 1.1 Use 2 mL each of βEcd and βEcd-combo in osteogenic medium (ThemoFisher Scientific) at 10 -7 Mol cultured bone marrow stromal cells for 28 days. Osteogenic gene expression (RUNX2 and Bgalp) was measured on day 7 and eligibility for bone mineralization nodule formation was measured on day 21. The result is as figure 1 shown. This result indicated that βEcd-combo was more able to promote osteogenesis in vitro by the fold change compared with βEcd control treatment. exist figure 1 In the histogram of osteogenic gene expression, the results given are that βEcd-combo is more effective than βEcd in promoting osteogenic RUNX2 and Bgalp gene expression.

[0037] 1.2 Mix bone marrow stromal cells with 2 mL each of βEcd and βEcd-combo in 10 -7 Mol was cultured for 28 days and then stained for crystal violet representing total colony formation. The same cell culture wells were then used ...

Embodiment 2

[0038] Example 2: Effect test of ecdysterone composition (βEcd-combo) on osteoporosis caused by estrogen deficiency

[0039]2.1 Two-month-old female mice were randomly divided into 3 experimental groups, with 8 animals in each group. Group 1, normal mice, ie control group; Group 2, ovariectomized group (OVX); treatment started immediately after OVX. Group 3, ovariectomized + βEcd-combo (OVX + βEcd-combo, oral gavage βEcd-combo, the dosage is equivalent to 0.5mg / kg Achyranthes bidentata, 0.25mg / kg quinoa, 0.25mg / kg white mulberry leaf , administered 5 times a week, that is, 5 days of administration per week and 2 days of withdrawal). Mice were euthanized 4 weeks after dosing.

[0040] 2.1.1 Cancellous bone test results see image 3 .

[0041] The results showed that bone mass and bone formation (total amount of white fluorescently labeled bone surface) were reduced after estrogen deficiency (ovariectomy). In this primary osteoporosis model, administration of the ecdysteron...

Embodiment 3

[0044] Embodiment 3: The impact test of ecdysterone composition (βEcd-combo) on the osteoporosis induced by glucocorticoid

[0045] 3.1 Two-month-old male Swiss-Webster mice were randomly divided into 4 experimental groups, with 8 mice in each group. The implantation method of sustained-release pellets of prednisolone (GC) (Innovative Research Corporation of America, Sarasota, Florida) was as follows: Group 1, control group, implanted placebo pellets (PL); group, implanted PL pellets + βEcd (PL+βEcd-combo 0.5mg / kg, administered 5 times a week); group 3, implanted prednisolone 5mg / 60-day sustained-release pellets, equivalent to 2.8 mg / kg / d (GC); the 4th group, implanted prednisolone 5mg / 60 day sustained-release pellets+βEcd (GC+βEcd-combo, the dosage of ecdysterone composition is equivalent to 0.5mg / kg Achyranthes bidentata, 0.25mg / kg quinoa, 0.25mg / kg white mulberry leaves)), and the ecdysterone composition was administered orally, administered 5 times a week). Wherein, the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition for preventing and/or treating osteoporosis, which is characterized by comprising the following components in parts by weight: 15-150 parts of radix achyranthis bidentatae, 1-60 parts of quinoa and 1-60 parts of white mulberry leaf. The invention also provides application of the composition in preparation of medicines for preventing and/or treating osteoporosis. The osteoporosis disclosed by the invention comprises primary osteoporosis and secondary osteoporosis. The composition disclosed by the invention is remarkable in drug effect, simple in preparation method and suitable for various preparation types.

Description

technical field [0001] The invention belongs to the technical field of medicines, health products or food, and specifically relates to a composition for preventing and / or treating primary osteoporosis and secondary osteoporosis. Background technique [0002] Glucocorticoids (GCs) are frequently used in clinical medicine to treat non-communicable inflammatory diseases. However, the use of GCs results in rapid loss of trabecular bone mass and a high risk of fractures. Glucocorticoid-induced bone loss (GIOP) has important clinical implications. Epidemiological studies have found that 50% of chronic rheumatoid arthritis patients treated with GC will develop osteoporotic fractures. Baseline data from randomized clinical trials reported a prevalence of vertebral fractures of 30%. Other studies have found that bone loss, an important public health concern, has been studied by GC treatment in all races, regardless of gender. As patients treated with GC may require long-term trea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/605A61P19/10
CPCA61K36/21A61K36/605A61K36/185A61P19/10A61K2300/00Y02A50/30
Inventor 陈继伟向雪香
Owner 中山莱博瑞辰生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap